Ann: Unlocking New Bedout Resources, page-15

First 15 Last

Share
Profile

Follow
wishlist

1,391 Posts.

213

31/08/23

13:01

Post #: 69662211
Share

Originally posted by peter63: ↑

From today's West Australian newspaper:

Carnarvon cites Santos over delays on project

JORDAN MURRAY
Carnarvon Energy chairman Bill Foster has taken Dorado project partner Santos to task for development delays he believes has led to the gas explorer’s “disappointing” share price in recent months.
Those comments — in the company’s end-of-financialyear report released on Wednesday — come after Carnarvon earlier in August sold half its stake in its Bedout assets to CPC Taiwan for $US146m ($225m).
Santos owns 80 per cent of Dorado, located within the Bedout sub-basin off Port Hedland, with the remaining 20 per cent evenly split between Carnarvon and CPC.
Project delays were flagged as early as August 2022, when Carnarvon cited inflationary pressure and supply chain uncertainties as a reason to push back a final investment decision.
And while a decision is now slated for 2024, Mr Foster used Wednesday’s report to air “personal frustration” with the project’s partners, implying Santos was to blame for delays.
“Our partner and operator of the Dorado development has not progressed development activity at a pace that Carnarvon wishes, despite best efforts by Carnarvon,” he said.
“This delay to FID had a knock-on impact to Carnarvon’s share price which was particularly disappointing for shareholders.
“Strategically, we had been running multiple funding options that enabled us to secure capital for the Dorado development from an asset sell-down rather than an equity raising.”
Managing director Adrian Cook similarly said Dorado had been “technically ready” for FID in the past year. “Disappointingly, at the end of the period, the FID for the Dorado development is yet to be realised, with the joint venture planning for FID in 2024,” he said.
A spokesperson for Santos declined to address the matter when sought for comment.
The financial results showed Carnarvon reported a loss of $4.1m in the year to June.
The explorer’s cash position fell from $112.4m to $95.3m in that time, however, those figures were reported before Carnarvon finalised the sell down in its Dorado stake.

Expand

The financial results showed Carnarvon reported a loss of $4.1m in the year to June.
The explorer’s cash position fell from $112.4m to $95.3m in that time
Funny those figures don’t add up
I would like to claim the change

CVN Price at posting: 15.8¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 37 more messages in this thread...

First 15 Last

Add CVN (ASX) to my watchlist

(20min delay)
Last 17.5¢		Change 0.010(6.06%)		Mkt cap ! $313.0M

Open	High	Low	Value	Volume
16.5¢	17.5¢	16.5¢	$208.3K	1.228M

Buyers (Bids)

No.	Vol.	Price($)
2	265525	17.0¢

Sellers (Offers)

Price($)	Vol.	No.
17.5¢	615505	12

View Market Depth

No.	Vol.	Price($)
2	265525	0.170
4	1055635	0.165
4	258985	0.160
7	206587	0.155
7	283335	0.150

Price($)	Vol.	No.
0.175	615505	12
0.180	806225	11
0.185	888213	7
0.190	810388	4
0.195	166549	3

Last trade - 16.10pm 07/10/2024 (20 minute delay)

CVN (ASX) Chart

Ann: Unlocking New Bedout Resources, page-15

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Unlocking New Bedout Resources, page-15

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News